Dapa Met 5/1000 Mg Tablets 28s – Comprehensive Control for Type 2 Diabetes
Dapa Met 5/1000 Mg Tablets 28s – Comprehensive Control for Type 2 Diabetes
Dapa Met 5/1000 Mg Tablets 28s – Comprehensive Control for Type 2 Diabetes
Description
Dapa Met 5/1000 Mg Tablets – Dual-Action SGLT2 Inhibitor and Biguanide Combination
Dapa Met 5/1000 Mg Tablets combine dapagliflozin 5mg, an SGLT2 inhibitor, with metformin 1000mg, a biguanide, to effectively manage type 2 diabetes mellitus in adults by addressing multiple pathways of glucose regulation. Dapagliflozin promotes glucose excretion through the kidneys, while metformin reduces hepatic glucose production and improves insulin sensitivity, resulting in better blood sugar control with a lower risk of hypoglycemia compared to some other therapies. This prescription medication, available in a 28-tablet pack for monthly dosing, also offers cardiovascular and renal protective benefits, making it suitable for patients needing enhanced glycemic management alongside lifestyle changes under medical supervision.
